**S1 Table:**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **%IFNγ** | **%TNFα** | **%IL2** | **%IL17** | **%IL22** | **%any IFNγ,TNFα IL2** | **%any IFNγ,IL2, IL17,IL22** |
| **DAR-901 treatment group** | **DAR-901 lysate stimulant** | **Baseline vs  post-dose 3 D7** | 0.0078 \*\* | 0.0391 \* | 0.0078 \*\* | 0.0547 | 0.3828 | 0.0039 \*\* | 0.0039 \*\* |
| **Baseline vs  post-dose 3 D180** | 0.0781 | 0.0977 | 0.1289 | 0.4258 | 0.2031 | 0.1641 | 0.0547 |
| **post-dose 3 D7 vs**  **post-dose 3 D180** | 0.0078 \*\* | 0.3125 | 0.0547 | 0.1094 | 0.5469 | 0.0078 \*\* | 0.0156 \* |
| **MTB lysate stimulant** | **Baseline vs  post-dose 3 D7** | 0.7344 | 0.8203 | 0.7344 | 0.5703 | 0.4258 | 0.5703 | 0.6250 |
| **Baseline vs  post-dose 3 D180** | 0.8203 | 0.5703 | 0.1953 | 0.7344 | 0.7344 | 0.7344 | 0.9102 |
| **post-dose 3 D7 vs**  **post-dose 3 D180** | 0.9453 | 0.9453 | 0.9453 | 0.2188 | 0.7109 | 0.1953 | 0.4609 |